HGP 0918

Drug Profile

HGP 0918

Alternative Names: HGP0918

Latest Information Update: 25 Nov 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Hanmi Pharmaceutical
  • Class Antihyperlipidaemics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Hyperlipidaemia

Most Recent Events

  • 01 Jun 2016 Hanmi Pharmaceuticals initiates enrolment in a phase I trial in Hyperlipidaemia (In volunteers) in South Korea (PO) (NCT02941796)
  • 01 Jul 2015 Phase-I clinical trials in Hyperlipidaemia (In volunteers) in South Korea (PO) (NCT02554136)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top